Our data demonstrate the existence of a lung CSC population and suggest a role for targeting ALDH1 as a potential therapeutic strategy in re-sensitizing NSCLC cells to the cytotoxic effects of cisplatin. The gene discussed is ALDH1A1; the disease is non-small cell lung carcinoma.